• Rhythm Pharmaceuticals highlighted IMCIVREE as the only approved therapy for acquired hypothalamic obesity, citing Phase 3 BMI change of -16.4% at 52 weeks.
• Placebo arm showed +2.4% BMI change; placebo-adjusted difference was -18.8% with P<0.0001 in the primary analysis cohort of 142 patients.
• U.S. launch metrics as of May 1, 2026: more than 150 patient start forms, about 110 unique prescribers, about 80% new prescribers.
• Cash, cash equivalents, short-term investments totaled $340.6 million as of March 31, 2026; 68 million common shares outstanding as of May 1, 2026.
• Pipeline focus on next-generation MC4R agonists; pivotal Phase 3 start for oral bivamelagon in acquired hypothalamic obesity targeted for year-end 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief on May 26, 2026, and is solely responsible for the information contained therein.